Morpholino

MO1-arhgef12b

ID
ZDB-MRPHLNO-200915-2
Name
MO1-arhgef12b
Previous Names
None
Target
Sequence
5' - CACCAGTCTGAACACCAGCTCGCAT - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-arhgef12b
No data available
Phenotype
Phenotype resulting from MO1-arhgef12b
No data available
Phenotype of all Fish created by or utilizing MO1-arhgef12b
Phenotype Fish Conditions Figures
nucleate erythrocyte hemoglobin amount, ameliorated WT + MO1-arhgef12a + MO1-arhgef12b chemical treatment by injection: (-)-anisomycin Fig. 4 from Xie et al., 2019
nucleate erythrocyte hbbe2 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue hbae1.1 expression spatial pattern, ameliorated WT + MO1-arhgef12a + MO1-arhgef12b chemical treatment by injection: (-)-anisomycin Fig. 4 from Xie et al., 2019
caudal hematopoietic tissue hbae1.1 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 4,  Fig. 5 from Xie et al., 2019
nucleate erythrocyte alas2 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte hbae1.1 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 4,  Fig. 5 from Xie et al., 2019
trunk hbae1.1 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue gata1a expression increased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue alas2 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue hbbe1.1 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte slc4a1a expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue hbae1.1 expression amount, ameliorated WT + MO1-arhgef12a + MO1-arhgef12b chemical treatment by injection: (-)-anisomycin Fig. 4 from Xie et al., 2019
nucleate erythrocyte hbae1.1 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 4,  Fig. 5 from Xie et al., 2019
caudal hematopoietic tissue alas2 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
erythroid progenitor cell gata1a expression increased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue gata1a expression increased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte alas2 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
erythrocyte differentiation decreased process quality, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 5 from Xie et al., 2019
caudal hematopoietic tissue hbbe2 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue hbbe1.1 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte hbae1.1 expression amount, ameliorated WT + MO1-arhgef12a + MO1-arhgef12b chemical treatment by injection: (-)-anisomycin Fig. 4 from Xie et al., 2019
nucleate erythrocyte hbbe1.1 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
erythroid progenitor cell gata1a expression increased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
erythroid lineage cell hemoglobin decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 4 from Xie et al., 2019
nucleate erythrocyte hemoglobin decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 4 from Xie et al., 2019
caudal hematopoietic tissue hbae1.1 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3,  Fig. 4,  Fig. 5 from Xie et al., 2019
trunk hbae1.1 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue slc4a1a expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue hbbe2 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
caudal hematopoietic tissue slc4a1a expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte hbae1.1 expression spatial pattern, ameliorated WT + MO1-arhgef12a + MO1-arhgef12b chemical treatment by injection: (-)-anisomycin Fig. 4 from Xie et al., 2019
nucleate erythrocyte hbbe1.1 expression decreased amount, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte slc4a1a expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
nucleate erythrocyte hbbe2 expression decreased distribution, abnormal WT + MO1-arhgef12a + MO1-arhgef12b control Fig. 3 from Xie et al., 2019
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.